[Transcatheter arterial chemotherapy with miriplatin for patients with hepatocellular carcinoma and chronic renal failure].

Abstract

Miriplatin is a novel lipophilic platinum complex developed to treat hepatocellular carcinoma (HCC). Although HCC patients frequently have coexisting chronic renal failure, there is no reliable data regarding clinical toxicity of miriplatin in HCC patients with chronic renal failure. We retrospectively evaluated the safety and efficacy of transcatheter arterial chemotherapy with miriplatin in 67 HCC patients with chronic renal failure (estimated glomerular filtration rate [GFR] by the Cockcroft-Gault equation <60ml/min). Estimated GFR within 2 months after miriplatin administration did not decrease significantly by the Wilcoxon signed rank test (pretreatment;46ml/min, 1 month;48ml/min;P=0.019, 2 months;45ml/min;P=0.619 [P<0.003 was significant by the Bonferroni correction]). Complete response in terms of tumor necrosis was achieved in 14 of 67 patients and no serious adverse events were observed. These results suggested that transcatheter arterial chemotherapy with miriplatin can be used safely for HCC patients with chronic renal failure.

• Authors: Norihiro Imai, Kenji Ikeda, Yuya Seko, Naoki Matsumoto, Yusuke Kawamura, Tetsuya Hosaka, Masahiro Kobayashi, Satoshi Saitoh, Hitomi Sezaki, Norio Akuta, Fumitaka Suzuki, Yoshiyuki Suzuki, Yasuji Arase, Hiromitsu Kumada
• Journal: Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology (Nihon Shokakibyo Gakkai Zasshi) Vol. 108 Issue 11 Pg. 1872-8 (Nov 2011) ISSN: 1349-7693 [Electronic] Japan
• PMID: 22056708 (Publication Type: English Abstract, Journal Article)

Chemical References

• Antineoplastic Agents
• Organoplatinum Compounds
• miriplatin

Topics

• Aged
• Aged, 80 and over
• Antineoplastic Agents (administration & dosage)
• Carcinoma, Hepatocellular (complications, drug therapy)
• Catheterization
• Female
• Humans
• Infusions, Intra-Arterial
• Kidney Failure, Chronic (complications)
• Liver Neoplasms (complications, drug therapy)
• Male
• Middle Aged
• Organoplatinum Compounds (administration & dosage)
• Retrospective Studies
• Treatment Outcome